Cogent Biosciences signs commercial supply deal with Hovione for bezuclastinib
The agreement, dated September 1, 2026, covers manufacturing of bezuclastinib's spray-dried dispersion and tablet forms.
SEC filing
Latest
3 stories
Wednesday, September 2
Monday, August 10
Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates ahead
The company said it is on track for potential approvals in GIST and non-advanced systemic mastocytosis this year, with a third NDA for advanced disease submitted in June.
SEC filing
Cogent Biosciences files $400 million stock offering under existing at-the-market program
The company amended its Guggenheim Securities sales agreement to sell up to $400 million in common stock as its bezuclastinib program awaits three FDA decisions.
SEC filing